Antipsychotic Medicine and Metabolic Syndrome (AMMS1)
Recruitment status was: Recruiting
The purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and a quality of life.
The investigators expect, that 30-50% of patients will show pharmacon - gene induced weight gain (> 7% of initial bodyweight) while the rest of patients will maintain unaltered bodyweight.
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Changes in Enteroendocrine and Neuroendocrine Axes in Patients With Weight Gain After Treatment With Antipsychotics|
|Study Start Date:||February 2008|
|Estimated Study Completion Date:||December 2010|
|Estimated Primary Completion Date:||February 2010 (Final data collection date for primary outcome measure)|
Food challenge test
51 patients included
Controls 93 healthy controls are included
The primary aim of this study is to investigate status of neuro-and enteroendocrine axes with focus on beta - cell function in relation to insulin resistance, lipid profile abnormalities and inflammations adipokins in patients during treatment with antipsychotics (AP) in relation to weight gain.
The second aim is to evaluate the connection between weight gain and patients´ own perception of their quality of life and health.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00627757
|Psychiatric University Center Glostrup|
|Copenhagen, Glostrup, Denmark, 2600|
|Principal Investigator:||Henrik Lublin, MD DMSc||Glostrup University Hospital, Copenhagen|